Controlled ovarian hyperstimulation (COH) which combines GnRH antagonist co-treatment and GnRHa trigger has recently become a common tool aiming to eliminate severe early OHSS and to support the concept of an OHSS-free clinic[4,5]. The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.